Skip to content

Clinical study on the treatment of herpes zoster neuralgia with platelet-rich plasma combined with spinal cord electrical stimulation

Clinical study on the treatment of herpes zoster neuralgia with platelet-rich plasma combined with spinal cord electrical stimulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112786
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-09-10
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes Zoster Neuralgia

Interventions

SCS Group:Perform spinal cord stimulation implantation (SCS)
Combined treatment group:Spinal cord stimulation combined with platelet-rich plasma injection

Sponsors

Jiangyou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age: 50 to 85 years old, gender not limited. 2. Consistent with the diagnosis of herpes zoster neuralgia (ZRN), the course of the disease is less than 3 months. 3. The Visual Analogue Scale (VAS) for pain at admission was >=4 points. 4. Voluntarily sign the informed consent form and be able to cooperate with the follow-up plan.

Exclusion criteria

Exclusion criteria: 1. Immunosuppressive status: Currently undergoing chemotherapy, biological agents, long-term glucocorticoids (>2 weeks), organ transplantation, or HIV positive. 2. Hematological abnormalities: Platelet count 1.5, or anticoagulant drugs are currently in use and cannot be discontinued. 3. Contraindications for puncture: Local skin infection, coagulation dysfunction, severe spinal deformity, or implantation of metal/pacemaker in the body that hinders SCS operation. 4. Coexisting with other chronic pain diseases (such as diabetic peripheral neuropathy, trigeminal neuralgia) may affect the evaluation of therapeutic efficacy. 5. Pregnancy, lactation or planning to become pregnant within 6 months. 6. Mental or cognitive impairment, unable to complete the scale assessment. 7. It is expected that the 3-month follow-up cannot be completed (severe comorbidities or life expectancy <3 months).

Design outcomes

Primary

MeasureTime frame
Pain score;

Secondary

MeasureTime frame
Quality of life;Sleep quality;Depression score;Inflammatory indicators;Dosage of analgesic drugs;

Countries

China

Contacts

Public ContactGuangyang Zhu

Jiangyou People's Hospital

yangguang_725@126.com+86 151 8144 9278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026